E-PaperDr Reddys Laboratories Q4 Results Live : profit rise by 36.41% YOY
Dr Reddys Laboratories Q4 Results Live : Revenue increased by 12.65% YoY & profit increased by 36.41% YoY
Dr Reddys Laboratories Q4 Results Live : Dr Reddys Laboratories declared their Q4 results on 07 May, 2024, with the topline increasing by 12.65% and the profit increasing by 36.41% YoY.
However, compared to the previous quarter, the revenue declined by 1.7% and the profit decreased by 5.15%.
The Selling, general & administrative expenses rose by 5.98% q-o-q and increased by 13.38% Y-o-Y.
The operating income was down by 11.28% q-o-q but increased by 20.11% Y-o-Y.
The EPS for Q4 is ₹77.68, which increased by 29.45% Y-o-Y.
Dr Reddys Laboratories has delivered -0.63% return in the last 1 week, 15.79% return in the last 6 months, and 7.93% YTD return.
The company currently has a market cap of ₹104206.9 Cr and a 52wk high/low of ₹6505.9 and ₹4384.05 respectively.
As of 09 May, 2024, out of 33 analysts covering the company, 3 analysts have given a Strong Sell rating, 8 analysts have given a Sell rating, 11 analysts have given a Hold rating, 6 analysts have given a Buy rating, and 5 analysts have given a Strong Buy rating.
The consensus recommendation as of 09 May, 2024, was to Hold.
Dr Reddys Laboratories Financials
| Period | Q4 | Q3 | Q-o-Q Growth | Q4 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 7113.8 | 7236.8 | -1.7% | 6315.2 | +12.65% |
| Selling/ General/ Admin Expenses Total | 3207.8 | 3026.7 | +5.98% | 2829.2 | +13.38% |
| Depreciation/ Amortization | 367.7 | 373.5 | -1.55% | 315.5 | +16.55% |
| Total Operating Expense | 5650.3 | 5587.2 | +1.13% | 5096.7 | +10.86% |
| Operating Income | 1463.5 | 1649.6 | -11.28% | 1218.5 | +20.11% |
| Net Income Before Taxes | 1605.2 | 1829.1 | -12.24% | 1329.2 | +20.76% |
| Net Income | 1309.8 | 1380.9 | -5.15% | 960.2 | +36.41% |
| Diluted Normalized EPS | 77.68 | 83.31 | -6.75% | 60.01 | +29.45% |
- Top Gainers
- Top Losers
- 52 Week High
